INT51883

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.15
First Reported 1995
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 3
Disease Relevance 0.74
Pain Relevance 0.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (ADAMTS2) extracellular region (ADAMTS2) proteinaceous extracellular matrix (ADAMTS2)
Anatomy Link Frequency
knee joint 1
ADAMTS2 (Homo sapiens)
Pain Link Frequency Relevance Heat
metalloproteinase 1 100.00 Very High Very High Very High
Pain 1 63.04 Quite High
tolerance 1 38.00 Quite Low
Glutamate 6 5.00 Very Low Very Low Very Low
nMDA receptor 5 5.00 Very Low Very Low Very Low
Central nervous system 3 5.00 Very Low Very Low Very Low
nMDA receptor antagonist 3 5.00 Very Low Very Low Very Low
Inflammation 2 5.00 Very Low Very Low Very Low
Neurotransmitter 2 5.00 Very Low Very Low Very Low
ketamine 1 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Disease 50 85.60 High High
Diabetes Mellitus 12 81.48 Quite High
Hyperglycemia 4 80.64 Quite High
Aggression 8 71.88 Quite High
Pain 1 63.04 Quite High
Injury 3 59.52 Quite High
Hallucination 3 58.72 Quite High
Disease Progression 2 32.64 Quite Low
Cognitive Disorder 15 27.76 Quite Low
Dementia 12 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The concentrations of cartilage proteoglycan (aggrecan), stromelysin-1, tissue inhibitor of metalloproteinases-1 (TIMP-1) and procollagen II C-propeptide in knee joint fluid and the levels of aggrecan, hyaluronan and keratan sulfate in serum were measured before and after exercise in 33 healthy athletes.
Negative_regulation (inhibitor) of C-propeptide in knee joint associated with metalloproteinase
1) Confidence 0.15 Published 1995 Journal Osteoarthr. Cartil. Section Abstract Doc Link 7719956 Disease Relevance 0.12 Pain Relevance 0.11
Maidment et al performed a meta-analysis of NPI scores from 5 RCT studies.54 The pooled study population included a total of 1750 patients, with 868 patients treated with meman-tine and 882 patients treated with placebo.22–24,57,58 Memantine was significnantly better than placebo on NPI outcome in 2 studies.23,57 The NPI change score non-significantly favored memantine in another 2 RCTs, and non-significantly favored placebo in a 1 trial.22,24,58 Using a random effects model, it was concluded that memantine significantly reduced the total mean NPI score (?
Negative_regulation (reduced) of NPI
2) Confidence 0.08 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2773287 Disease Relevance 0.46 Pain Relevance 0
This process is limited by the NPI mass loss during the experimental procedure indeed.
Negative_regulation (loss) of NPI
3) Confidence 0.02 Published 2010 Journal Stem Cells International Section Body Doc Link PMC2956457 Disease Relevance 0.16 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox